115P - Maintenance low-dose gemcitabine versus best supportive care in advanced and metastatic non-small cell lung cancer: randomized phase III trial

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Supportive Care
Non-Small-Cell Lung Cancer, Metastatic
Presenter Ahmed Nagy
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors A. Nagy, E. Fouad, K. Nasr, H. El-Ghazaly, A. Adel
  • Clinical Oncology And Nuclear Medicine, Ain Shams University Faculty of Medicine, 11566 - Cairo/EG


To evaluate efficacy (defined in terms of prolongation of Time to Progression and Overall survival) and safety (as regard grade 3 and 4 toxicity)of low-dose gemcitabine as maintenance chemotherapy after first line gemcitabine/cisplatin in advanced and metastatic NSCLC.